Four Bluejay shares will become one on Nov. 3
Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split, effective November 3, 2026. The company's common stock will trade under the same symbol, BJDX, with a new CUSIP number. Shareholders with certificates will receive exchange instructions, while others will see changes reflected in their accounts. Bluejay focuses on medical diagnostics, including its Symphony™ System for sepsis triage, which awaits FDA approval.
How this was made
The 30-second read
Why it matters
The reverse split changes the share count by a factor of four while leaving par value unchanged, which can alter per-share valuation metrics and short-term liquidity/volatility dynamics around Nov. 3.
Market read
This is a discrete corporate-action catalyst with a known effective date, making it actionable for positioning around the split and for managing liquidity and order execution expectations.
What to watch
Traders should monitor broker processing and any temporary trading frictions around the effective date, since holders in certificate form must exchange shares while book-entry holders typically see the change automatically.
Background
Bluejay Diagnostics is a near-patient diagnostics company with its Symphony platform and an IL-6 test candidate; the release notes it lacks US regulatory clearance for Symphony.
Ticker impact
Bluejay Diagnostics approved a 1-for-4 reverse stock split effective Nov. 3, which can materially affect share price, liquidity, and Nasdaq trading optics.
Likely near-term volatility and potential downward pressure if the market interprets the move as a continued capital-market stress signal, with the main driver being the mechanical share-count change and liquidity optics.
The article discloses the exact reverse split ratio and the effective trading date (Nov. 3) but provides no fundamental operational update; reverse splits commonly change per-share pricing and can affect investor perception and liquidity.
Market effects
For medical diagnostics microcaps, reverse splits can reflect ongoing financing or compliance pressures, potentially influencing sentiment toward similar pre-revenue or regulatory-stage names.
Primarily impacts US small-cap/Nasdaq Capital Market trading flows for the issuer.
Limited, as the event is company-specific and US-market microstructure driven.
Counterpoint
The reverse split may be a technical step to maintain listing compliance or improve trading liquidity, not necessarily a deterioration in fundamentals.
Key entities
- companyBluejay Diagnostics, Inc.
NASDAQ-listed medical diagnostics company announcing a 1-for-4 reverse stock split effective Nov. 3, 2026.
- service_providerContinental Stock Transfer & Trust Company
Transfer agent retained to act as exchange agent for the reverse stock split.
- venueNasdaq Capital Market
Exchange where the stock will open for trading on a post-split basis on Nov. 3, 2026.

